CN114555056B - 小分子PI4KIIIα抑制剂组合物、其制备方法及用途 - Google Patents

小分子PI4KIIIα抑制剂组合物、其制备方法及用途 Download PDF

Info

Publication number
CN114555056B
CN114555056B CN202080049288.5A CN202080049288A CN114555056B CN 114555056 B CN114555056 B CN 114555056B CN 202080049288 A CN202080049288 A CN 202080049288A CN 114555056 B CN114555056 B CN 114555056B
Authority
CN
China
Prior art keywords
pharmaceutical composition
amount
present
pi4kiii
small molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080049288.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN114555056A (zh
Inventor
黄福德
王峰
杨书
焦常平
周小军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nobetide Pharmaceutical Technology Shanghai Co ltd
Original Assignee
Nobetide Pharmaceutical Technology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobetide Pharmaceutical Technology Shanghai Co ltd filed Critical Nobetide Pharmaceutical Technology Shanghai Co ltd
Priority to CN202311755839.1A priority Critical patent/CN118105372A/zh
Publication of CN114555056A publication Critical patent/CN114555056A/zh
Application granted granted Critical
Publication of CN114555056B publication Critical patent/CN114555056B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202080049288.5A 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途 Active CN114555056B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311755839.1A CN118105372A (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/094831 2019-07-05
CN2019094831 2019-07-05
PCT/CN2020/100377 WO2021004422A1 (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311755839.1A Division CN118105372A (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
CN114555056A CN114555056A (zh) 2022-05-27
CN114555056B true CN114555056B (zh) 2024-01-05

Family

ID=74115038

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080049288.5A Active CN114555056B (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途
CN202311755839.1A Pending CN118105372A (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311755839.1A Pending CN118105372A (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Country Status (15)

Country Link
US (1) US20230115711A1 (cg-RX-API-DMAC7.html)
EP (1) EP3995134A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022538505A (cg-RX-API-DMAC7.html)
KR (1) KR20220071175A (cg-RX-API-DMAC7.html)
CN (2) CN114555056B (cg-RX-API-DMAC7.html)
AU (1) AU2020309681A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000155A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149104A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001218A2 (cg-RX-API-DMAC7.html)
IL (1) IL289586A (cg-RX-API-DMAC7.html)
MX (1) MX2022000287A (cg-RX-API-DMAC7.html)
PE (1) PE20220942A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550254A1 (cg-RX-API-DMAC7.html)
TW (1) TW202126294A (cg-RX-API-DMAC7.html)
WO (1) WO2021004422A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685566A (zh) * 2020-12-31 2022-07-01 江苏挪贝肽医药科技有限公司 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法
MX2024004055A (es) * 2021-09-30 2024-06-19 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo.
CN116478954B (zh) * 2023-02-14 2025-06-10 中国农业大学 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101688206A (zh) * 2007-07-05 2010-03-31 诺瓦提斯公司 用于靶向病毒感染的dsRNA
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365110A1 (en) * 2001-07-10 2003-07-15 Massachusetts Institute Of Technology Small molecule microarrays
WO2019200043A1 (en) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Coporation Lipid prodrugs for use in drug delivery
EP4130014A4 (en) * 2020-03-31 2024-05-15 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Deuterated oxophenylarsine compound and use thereof
MX2024004055A (es) * 2021-09-30 2024-06-19 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101688206A (zh) * 2007-07-05 2010-03-31 诺瓦提斯公司 用于靶向病毒感染的dsRNA
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
脂质纳米粒在口服给药系统中的应用;戚建平等;《生物化学与生物物理进展》;第40卷(第40期);第1008-1013页 *

Also Published As

Publication number Publication date
KR20220071175A (ko) 2022-05-31
CN118105372A (zh) 2024-05-31
EP3995134A4 (en) 2023-07-12
WO2021004422A1 (zh) 2021-01-14
JP2022538505A (ja) 2022-09-02
IL289586A (en) 2022-03-01
EP3995134A1 (en) 2022-05-11
CA3149104A1 (en) 2021-01-14
TW202126294A (zh) 2021-07-16
AU2020309681A1 (en) 2022-02-24
BR112022000155A2 (pt) 2022-04-12
PE20220942A1 (es) 2022-05-31
US20230115711A1 (en) 2023-04-13
CO2022001218A2 (es) 2022-05-20
PH12022550254A1 (en) 2023-06-26
MX2022000287A (es) 2022-06-16
CN114555056A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
AU2021269396B2 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
CA2824317C (en) Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
KR20200106049A (ko) 칸나비노이드 및 폴록사머를 포함하는 경구 약학 제형
JP2019519556A (ja) カンナビノイド製剤
CN118105372A (zh) 小分子PI4KIIIα抑制剂组合物、其制备方法及用途
PL213644B1 (pl) Zastosowanie glikozydów mono- i diacyloglicerolu do wytwarzania leku do leczenia, lagodzenia lub profilaktyki stanów zapalnych
WO2018191732A1 (en) Methods and compositions for treatment of inflammation and oxidative stress
US11684599B2 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
US20180200318A1 (en) Use of mangosteen rind extract in preparation of medicine for treating skin diseases
KR20250035567A (ko) 안정된 실로신 염, 에스테르 및 접합체의 제조 및 이의 용도
KR20180010181A (ko) Apo c3 의 저하를 위한 티아 옥소 화합물의 용도
US11273139B2 (en) Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
HK40074190A (en) MICROMOLECULE PI4KIIIα INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
HK40074190B (en) MICROMOLECULE PI4KIIIα INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
CN109985004A (zh) 氟比洛芬酯脂肪乳注射液、其制备方法及应用
HK40073830A (en) Micromolecule pi4kiiialpha inhibitor composition, preparation method therefor and use thereof
OA20568A (en) Micromolecule PI4Klllα inhibitor composition, preparation method therefor and use thereof.
CN116617203B (zh) 一种自乳化微乳组合物及其制备方法和应用
CN120004750B (zh) 一种无菌的双他喷他多癸二酸酯及其制备方法与用途
CN120058608B (zh) 可用于长效注射剂的喷他佐辛前药及制备方法与用途
EP4446306A1 (en) Cannabidiol derivative, preparation method therefor and application thereof
JP2023551415A (ja) カンナビジオールの固体分散体
JP2011126791A (ja) アレルギー疾患感受性遺伝子発現抑制物質
CA2880399C (en) Use of bimatoprost free acid administered to the skin to reduce adipose tissue

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074190

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
PP01 Preservation of patent right
PP01 Preservation of patent right

Effective date of registration: 20250312

Granted publication date: 20240105